- Home
- RPAY vs ELDN Comparison
RPAY vs ELDN Comparison
Compare RPAY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | ELDN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 291.8M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RPAY | ELDN |
|---|---|---|
| Price | $3.79 | $2.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $5.53 | ★ $8.50 |
| AVG Volume (30 Days) | 345.6K | ★ 931.2K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $309,261,000.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $4.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $1.35 |
| 52 Week High | $5.39 | $4.60 |
Technical Indicators
Market Signals| Indicator | RPAY | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 34.15 |
| Support Level | $3.47 | $2.63 |
| Resistance Level | $3.91 | $3.21 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.77 | 17.31 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.